Table 3

Adverse events among patients with BCC treated with PD-1 inhibition

Grade 1 (%)Grade 2 (%)Grade 3 (%)Grade 4 (%)Total (%)
Constitutional (fatigue)9 (31.0)1 (3.4)0 (0.0)0 (0.0)10 (34.5)
Dermatological (pruritus, rash)6 (20.7)1 (3.4)0 (0.0)0 (0.0)7 (24.1)
Endocrine (hypothyroidism)3 (10.3)1 (3.4)0 (0.0)0 (0.0)4 (13.8)
Gastrointestinal (diarrhea)1 (3.4)1 (3.4)1 (3.4)0 (0.0)3 (10.3)
Musculoskeletal (arthralgia)0 (0.0)2 (6.9)0 (0.0)0 (0.0)2 (6.9)
Liver (transaminitis)0 (0.0)0 (0.0)0 (0.0)1 (3.4)1 (3.4)
Renal (nephritis)0 (0.0)0 (0.0)0 (0.0)1 (3.4)1 (3.4)
Neurological (encephalitis)0 (0.0)1 (3.4)0 (0.0)0 (0.0)1 (3.4)
Infusion reaction0 (0.0)1 (3.4)0 (0.0)0 (0.0)1 (3.4)
  • BCC, basal cell carcinoma.